Horie A.,Diabetes Center |
Tokuyama Y.,Kashiwado Hospital |
Ishizuka T.,Sato Clinic |
Suzuki Y.,Asahi General Hospital |
And 5 more authors.
Hormone and Metabolic Research | Year: 2014
The aim of the present study was to determine whether the dipeptidyl peptidase (DPP)-4 inhibitor could repair pancreatic β-cell dysfunction and insulin resistance. Ten subjects with type 2 diabetes who had never received DPP-4 inhibitor treatment were enrolled in the study. Just before and 3 months after twice-daily administration of vildagliptin (50mg tablets), insulin secretion and insulin sensitivity were estimated using 2-compartment model analysis of C-peptide kinetics and insulin-modified minimal model parameters, respectively. The first-phase insulin secretion (CS1) was determined as the sum of the C-peptide secretion rate (CSR) from 0 to 5min (normal range 6.8-18.5ng/ml/min). The whole-body insulin sensitivity index (SI) was calculated using a minimal model software program (normal range 2.6-7.6×10-4/min/μU/ml). After vildagliptin treatment, reductions in mean (±SE) HbA1c were noted (43.28±1.53 vs. 40.98±1.77mmol/mol; p=0.019). Vildagliptin treatment increased the area under the curve for the C peptide reactivity (CPR) (AUCCPR; 26.66±5.15 vs. 33.02±6.12ng/ml·20min; p=0.003) and CS1 (0.80±0.20 vs. 1.35±0.38ng/ml/min; p=0.037) in response to an intravenous glucose load. Vildagliptin treatment significantly increased SI (0.46±0.27 vs. 1.21±0.48×10-4/min/μU/ml; p=0.037). The long-term administration of vildagliptin improved CS1 and Si suggesting that this drug has the capacity to repair impairments in pancreatic β-cell function and insulin resistance in type 2 diabetes. © Georg Thieme Verlag KG Stuttgart New York.
Aikawa T.,Aikawa Internal Medicine Hospital |
Sugiyama H.,Tsukuba Memorial Hospital |
Soeda A.,Tsukuba Memorial Hospital |
Ikezawa K.,Tsukuba Memorial Hospital |
And 4 more authors.
Acta Hepatologica Japonica | Year: 2014
To examine recent trends of acute infection with hepatitis B virus (HBV) in Mito, located in a non-Metropolitan area of Japan, serum samples obtained from 17 patients with acute hepatitis B (AHB) and 243 patients with chronic HBV infection during 2001-2013 were subjected to HBV genotyping. HBV genotype A (GtA) was detected in 3 (1%), GtB in 64 (26%) and GtC in 174 (72%) of patients with chronic HBV infection, while GtA was most prevalent (47%) among the AHB patients. Of note, GtA was found significantly more frequently in AHB patients during 2008-2013 than in those during 2001-2007 (64% vs. 17%, p<0.0001). These increasing trends of GtA HBV infection via sexual transmission emphasize the necessity of preventive education and measures. © 2014 The Japan Society of Hepatology.
Hiraga M.,Kirishima Medical Center |
Ikeda K.,Chiba University |
Shigeta K.,Kirishima Medical Center |
Sato A.,Sato Clinic |
And 3 more authors.
Modern Rheumatology | Year: 2015
Introduction. Assessment of synovitis in the metatarsophalangeal (MTP) joints with ultrasound has been shown to improve the accuracy of assessment of rheumatoid arthritis (RA). However, the presence of intraarticular low-echoic synovial area (LESA) in the MTP joints in healthy subjects complicates the sonographic assessment of these joints. Method. Healthy subjects with no arthritic symptoms in their MTP joints were recruited. All subjects completed a questionnaire and underwent physical examination and sonographic assessment. LESAs in the dorsal aspect of all MTP joints were measured in the longitudinal view. Results. One thousand non-arthritic MTP joints in 100 healthy subjects (female 73, mean age 41.0 years old) were evaluated. Measurable LESAs were identified in all joints assessed. Mean length of LESA in each of the 1st - 5th MTP joints was 17.8, 13.9, 11.9, 10.6, and 9.2 mm, respectively, whereas mean thickness was 2.4, 2.4, 1.8, 1.2, and 0.8 mm, respectively. Multivariate linear regression models identified the difference between 1st and 5th MTP joints as the most independently influential factor on the measurement of LESA. Conclusions. Our data provide the normal reference values for the measurements of LESA in Japanese, which should be taken into consideration when the synovitis in MTP joints is evaluated with ultrasound. © 2014 Japan College of Rheumatology.
Saito J.,Keio University |
Imamura Y.,Kogakuin University |
Itoh J.,Itoh Co. |
Matsuyama S.,Central Research Laboratory |
And 10 more authors.
Anticancer Research | Year: 2010
Background/Aim: We reported that endogenous urinary 3-hydroxyproline (3-Hyp) is useful for cancer screening because cancer invasion involves the destruction of basement membrane. A simple and sensitive assay is desired. Patients and Methods: An ELISA method using a specific antibody against a synthetic peptide of 10 amino acids including 3-Hyp corresponding to the amino acid sequences of collagen type IV alpha chain was applied to urine samples from 180 healthy controls and 22 cancer patients. Results: The values in controls were 2.44±1.90 (SD) mg peptide/g creatinine for 52 men and 2.87±2.01 for 128 women, while the values in 22 cancer patients were very low at 0.110±0.137 (p<0.001). Discussion: The discrepancy in the data between our previous and present studies is based on the difference of targets measured. 3-Hyp-containing peptides in cancer patients might be destroyed by the elevated peptidase levels found in these patients. Conclusion: This ELISA assay may be useful for cancer screening.
Shigematsu E.,Yokohama City University |
Yamakawa T.,Yokohama City University |
Taguri M.,Yokohama City University |
Morita S.,Yokohama City University |
And 7 more authors.
Journal of Atherosclerosis and Thrombosis | Year: 2012
Aim: The combination of ezetimibe and a statin provides greater LDL-C reduction by inhibiting both intestinal cholesterol absorption and endogenous production of cholesterol. The present study was designed to examine the influence of ageing, gender, BMI, levels of LDL-C, and HbA1c on the response to ezetimibe add-on therapy. Methods: Patients who had been taking a statin for >3 months at the usual dose and whose LDL-C was >120 mg/dL were eligible for this study. Patients were assigned to receive add-on ezetimibe at 10 mg once daily for 12 weeks. Results: Adding ezetimibe to basal statin therapy resulted in a further 15.0% reduction of TC, 20.5% reduction of LDL-C, and 19.7% reduction of non-HDL-C. The change in TC was significantly greater in males than in females. The change in TG was significantly greater in patients with a baseline TG level ≥150 mg/dL. Multivariate regression analysis showed that male sex and LDL-C ≥140 mg/dL were independent predictors of TC reduction after adjustment for age, BMI, and HbA1c. A baseline TG ≥150 mg/dL was also an independent predictor of TG reduction. Conclusion: Addition of ezetimibe to ongoing statin therapy was effective in patients with type 2 diabetes. Male sex and baseline LDL-C levels are independent predictors of marked TC reduction by ezetimibe treatment.